Production (Stage)
Acumen Pharmaceuticals, Inc.
ABOS
$1.02
-$0.01-0.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 117.26% | 109.33% | 154.03% | 98.92% | 79.56% |
| Gross Profit | -117.26% | -109.33% | -154.03% | -98.92% | -79.56% |
| SG&A Expenses | 1.39% | 7.43% | 19.00% | 31.93% | 40.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.49% | 86.49% | 63.28% | 46.81% | 33.79% |
| Operating Income | -92.49% | -86.49% | -63.28% | -46.81% | -33.79% |
| Income Before Tax | -107.83% | -95.39% | -67.57% | -39.51% | -24.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -107.83% | -95.39% | -67.57% | -39.51% | -24.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.83% | -95.39% | -67.57% | -39.51% | -24.21% |
| EBIT | -92.49% | -86.49% | -63.28% | -46.81% | -33.79% |
| EBITDA | -92.58% | -86.57% | -63.31% | -46.83% | -33.77% |
| EPS Basic | -83.07% | -57.53% | -23.25% | 2.07% | 4.52% |
| Normalized Basic EPS | -83.09% | -57.51% | -21.69% | 3.29% | 5.75% |
| EPS Diluted | -83.07% | -57.53% | -22.75% | 2.45% | 4.91% |
| Normalized Diluted EPS | -83.09% | -57.51% | -21.69% | 3.29% | 5.75% |
| Average Basic Shares Outstanding | 12.99% | 23.55% | 34.29% | 41.99% | 30.76% |
| Average Diluted Shares Outstanding | 12.99% | 23.55% | 34.29% | 41.99% | 30.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |